Screening tests are performed using reagent based systems that determine the presence or absence of drug compounds in the urine. While these tests can identify groups or classes of drug compounds that may be present in a patient sample, they can rarely be used to identify a specific drug or drug metabolite. This is why they are known as non-specific assays, and are considered presumptive screening tests. Another test is needed to determine exactly what drug compound, and what quantity, has triggered the positive presumptive screen.
Confirmatory tests are the next step in the testing process. To further pin-point the identity of a drug, an alternate methodology that is specific and sensitive to each individual drug compound must be employed. Kashi utilizes a state-of-the-art technology known as Liquid Chromatography/Mass Spectrometry (LC/MS) to confirm the presence and amount of specific drug compounds at the molecular level. LC/MS is capable of detecting a wide variety of compounds, including drugs, and is considered the “gold standard” by experts in many fields.